Siponimod (brand name Mayzent, Novartis) is a selective sphingosine-1-phosphate (S1P) receptor modulator already approved for multiple sclerosis (MS). It is now being repositioned for [Alzheimer's disease](/diseases/alzheimers-disease) based on compelling preclinical evidence showing neuroprotective and anti-inflammatory effects. A Phase II clinical trial (NCT06639282) is currently recruiting to evaluate the efficacy of siponimod in AD patients["@brock2022"][@selkoe2021].
Siponimod binds to S1P receptor subtypes 1 and 5 (S1P1R, S1P5R), modulating lymphocyte trafficking and exerting direct neuroprotective effects in the CNS. Unlike fingolimod (non-selective S1P modulator), siponimod's selectivity reduces cardiac side effects while maintaining therapeutic benefit.
Mechanism of Action
S1P Receptor Modulation
Siponimod acts as a functional antagonist at S1P1R and agonist at S1P5R:
S1P1R (lymphocytes): Internalization and degradation → reduced lymphocyte egress from lymph nodes → fewer pro-inflammatory T cells entering the CNS
S1P5R (CNS): Direct neuroprotective signaling in oligodendrocytes, astrocytes, and neurons
Neuroprotective Effects in AD
Siponimod provides benefit through multiple mechanisms[@paris2019]:
Aβ-induced neurotoxicity: S1P5R activation protects neurons from amyloid-β oligomer toxicity
Microglial modulation: Shifts microglia toward the protective M2 phenotype
Tau phosphorylation: S1P signaling reduces GSK-3β activity, lowering tau phosphorylation
Key findings supporting siponimod in AD[@brock2022][@paris2019]:
APP/PS1 mice: Siponimod treatment reduced amyloid plaque load by ~30%, improved spatial memory (Morris water maze), and preserved synaptic density
3xTg-AD mice: Reduced tau phosphorylation and improved cognitive performance
Human data: S1P receptor expression is altered in AD brain tissue; S1P levels are reduced in CSF from AD patients
Comparison with Fingolimod
S1P Receptor Biology and Neuroprotection
Sphingosine-1-phosphate (S1P) is a bioactive lipid signaling molecule that regulates diverse cellular processes through five G protein-coupled receptor subtypes (S1P1R-S1P5R)[@oukolov2020]. In the CNS, S1P signaling is involved in:
Neuronal survival: S1P5R activation promotes pro-survival signaling via PI3K/Akt and MAPK/ERK pathways
Oligodendrocyte function: S1P1R and S1P5R regulate oligodendrocyte precursor cell migration, differentiation, and myelination
Microglial polarization: S1P receptors influence microglial phenotype switching between M1 (pro-inflammatory) and M2 (protective)
S1P Receptor Subtype Distribution
Neuroprotective Mechanisms in AD
Siponimod provides multi-modal neuroprotection through the following pathways[@paris2019][@selkoe2021]:
Modulation of Aβ-induced toxicity: S1P5R activation in hippocampal and cortical neurons upregulates BDNF expression and activates TrkB signaling, conferring resistance to amyloid-β oligomer toxicity. Preclinical studies in APP/PS1 mice showed 30% reduction in amyloid plaque burden with siponimod treatment.
Microglial phenotype shift: Siponimod promotes switching from M1 (CD16/32+, IL-1β+, TNF-α+) to M2 (CD206+, Arg1+, IL-10+) phenotype via S1P1R on microglia. This reduces pro-inflammatory cytokine release and enhances phagocytic clearance of Aβ deposits.
Tau phosphorylation reduction: S1P signaling via S1P5R inhibits GSK-3β activity through PP2A activation, reducing tau phosphorylation at AD-relevant epitopes (Ser396, Thr231). This may limit NFT formation.
Synaptic protection: Siponimod inhibits complement C1q-mediated synaptic pruning by reducing microglial C1q expression. This preserves glutamatergic synapse density, which is critical for memory function.
Blood-brain barrier repair: S1P1R activation on endothelial cells promotes BBB integrity by stabilizing VE-cadherin junctions and reducing matrix metalloproteinase-9 (MMP-9) activity, limiting peripheral immune cell infiltration.
Lipid raft modulation: S1P receptors localize to membrane lipid rafts where they regulate APP processing. Siponimod reduces BACE1 activity through raft modulation, lowering Aβ generation.
Pharmacokinetics
Absorption: Rapid oral absorption, Tmax ~4 hours
Bioavailability: ~87% (food has minimal effect)
Distribution: High tissue penetration, including CNS (brain-to-plasma ratio ~10:1)
Metabolism: Hepatic (CYP2C9, CYP3A4), producing active metabolites